Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 7;20(1):20251235.
doi: 10.1515/med-2025-1235. eCollection 2025.

Uterine fibroid embolization: An analysis of clinical outcomes and impact on patients' quality of life

Nicolò Ubaldi  1   2 , Marcello Andrea Tipaldi  1   2 , Andrea Giannini  3 , Tullio Golia D'Augè  4 , Donatella Caserta  3 , Antonio Simone Laganà  5 , Giacomo Grasso  1 , Aleksejs Zolovkins  2 , Edoardo Ronconi  2 , Michele Rossi  1   2
Affiliations

Uterine fibroid embolization: An analysis of clinical outcomes and impact on patients' quality of life

Nicolò Ubaldi et al. Open Med (Wars). .

Abstract

Background: Uterine fibroids (UF) affect up to 70-80% of women by age 50 and are associated with heavy menstrual bleedings, pelvic discomfort, and reduced quality of life. Uterine artery embolization (UAE) is a minimally invasive procedure that aims to reduce fibroid-related symptoms and improve patients' quality of life.

Materials and methods: A prospective single-center study was conducted on 40 women who underwent UAE between November 2018 and June 2023. Primary outcomes were evaluated using the Uterine Fibroid Symptom and Quality-of-Life (UFS-QoL) questionnaire to assess symptom severity and health-related quality-of-life scores. Secondary outcomes include pain intensity, complications, requirement of additional treatments, and duration of symptoms after discharge.

Results: Thirty-three patients completed the follow-up UFS-QoL questionnaire. The mean age and the mean follow-up time were 47 years (SD 14 years) and 10 months (SD 4 months), respectively. Substantial improvements were observed within all domains of the UFS-QoL questionnaire (p < 0.001), particularly in symptom severity, where 94% of patients experienced a benefit. All Health Related Quality-of-Life (HRQL) domains statistically significantly improved (73-91%; p < 0.001). 67% of patients did not require further treatments. Pelvic pain, according to VAS, improved by 2.1 (0 = much better; 5 = no change; 10 = worse). Post-procedural complications were minor, 70% of patients reported symptoms persisted up to 5 days after discharge, and 88% resolved within 2 weeks. Despite a 45.5% rate of minor complications, including pain and transitory bleeding, 88% of patients would recommend UAE, underlining its safety and effectiveness.

Discussion and conclusion: UAE offers substantial benefits for symptomatic fibroids, significantly improving HRQoL, symptom severity and pelvic pain scores, making it a valuable alternative to surgery. Complications were minor and short-lived, and the majority of patients were satisfied with the results, with no need for additional treatments. Further research is warranted to generate peri-procedural pain management consensus guidelines, clinical outcomes of radial access, and fertility-related outcomes.

Keywords: quality of life; symptom severity; uterine artery embolization; uterine fibroid.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Tullio Golia D’Augè and Antonio Simone Laganà serve as an editors for the journal; however, this role did not influence the editorial processing or the peer review of this article. The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the study population selection.
Figure 2
Figure 2
Pain score in the hours following the operation, measured on an NPRS scale.
Figure 3
Figure 3
VAS Response scores after UAE.
Figure 4
Figure 4
Duration of symptoms after UAE.
Figure 5
Figure 5
Number of patients who underwent re-treatment (UAE) or different therapies.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: A systematic review. BJOG. 2017;124:1501–12. - PubMed
    1. Drayer SM, Catherino WH. Prevalence, morbidity, and current medical management of uterine leiomyomas. Int J Gynaecol Obstet. 2015;131:117–22. - PubMed
    1. Guo XC, Segars JH. The impact and management of fibroids for fertility: an evidence-based approach. Obstet Gynecol Clin North Am. 2012;39:521–33. - PMC - PubMed
    1. Giannini A, Golia D’Augè T, Bogani G, Laganà AS, Chiantera V, Vizza E, et al. Uterine sarcomas: A critical review of the literature. Eur J Obstet Gynecol Reprod Biol. 2023;287:166–70. - PubMed
    1. Ravina JH, Herbreteau D, Ciraru-Vigneron N, Bouret JM, Houdart E, Aymard A, et al. Arterial embolisation to treat uterine myomata. Lancet. 1995;346:671–2. - PubMed

LinkOut - more resources